je.st
news
New KEYTRUDA (pembrolizumab) Data in Blood Cancers to be Presented at 58th Annual Meeting of the American Society of Hematology
2016-11-22 13:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Updated Findings with Longer Follow-Up in Classical Hodgkin Lymphoma to be Featured in Oral Presentations KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data regarding the investigational use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in patients with a range of blood cancers including classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma, will be presented at the 58th Annual Meeting of the American Society of Hematology (ASH) in San Diego, Dec. 3-6. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: the
of
data
american
Category:Biotechnology and Pharmaceuticals